Login to Your Account



Clinic Roundup


Tuesday, January 8, 2013
• Edison Pharmaceuticals Inc., of Mountain View, Calif., said it started a Phase IIb study testing EPI-743 in patients with Friedreich's ataxia. The six-month study, expected to be followed by an extension phase, will enroll patients between the ages of 18 and 45 who possess genetic confirmation of Friedreich's ataxia.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription